{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T17:45:34Z","timestamp":1760550334966},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,7,31]],"date-time":"2017-07-31T00:00:00Z","timestamp":1501459200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1007\/s10147-017-1175-1","type":"journal-article","created":{"date-parts":[[2017,7,30]],"date-time":"2017-07-30T21:50:09Z","timestamp":1501451409000},"page":"165-172","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["The 5-year outcomes of moderately hypofractionated radiotherapy (66\u00a0Gy in 22 fractions, 3 fractions per week) for localized prostate cancer: a retrospective study"],"prefix":"10.1007","volume":"23","author":[{"given":"Yaichiro","family":"Hashimoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Motegi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuo","family":"Akimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norio","family":"Mitsuhashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junpei","family":"Iizuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazunari","family":"Tanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuka","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sawa","family":"Kono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sachiko","family":"Izumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kumiko","family":"Karasawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,7,31]]},"reference":[{"key":"1175_CR1","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1016\/j.ijrobp.2010.10.075","volume":"82","author":"R Miralbell","year":"2012","unstructured":"Miralbell R, Roberts SA, Zubizarreta E et al (2012) Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5969 patients in seven international institutional datasets: \u03b1\/\u03b2\u00a0=\u00a01.4 (0.9\u20132.2) Gy. Int J Radiat Oncol Biol Phys 82:e17\u2013e24","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1175_CR2","doi-asserted-by":"crossref","first-page":"963","DOI":"10.3109\/0284186X.2012.719635","volume":"51","author":"A Dasu","year":"2012","unstructured":"Dasu A, Toma-Dasu I (2012) Prostate alpha\/beta revisited\u2014an analysis of clinical results from 14,168 patients. Acta Oncol 51:963\u2013974","journal-title":"Acta Oncol"},{"key":"1175_CR3","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.ijrobp.2004.04.014","volume":"60","author":"DJ Brenner","year":"2004","unstructured":"Brenner DJ (2004) Fractionation and late rectal toxicity. Int J Radiat Oncol Biol Phys 60:1013\u20131015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1175_CR4","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.ijrobp.2010.11.080","volume":"81","author":"SL Tucker","year":"2011","unstructured":"Tucker SL, Thames HD, Michalski JM et al (2011) Estimation of \u03b1\/\u03b2 for late rectal toxicity based on RTOG 94-06. Int J Radiat Oncol Biol Phys 81:600\u2013605","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1175_CR5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.clon.2016.09.020","volume":"29","author":"D Dearnaley","year":"2017","unstructured":"Dearnaley D, Syndikus I, Gulliford S et al (2017) Hypofractionation for prostate cancer: time to change. Clin Oncol 29:3\u20135","journal-title":"Clin Oncol"},{"key":"1175_CR6","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/nrclinonc.2016.147","volume":"13","author":"A Pollack","year":"2016","unstructured":"Pollack A, Abramowitz M (2016) Prostate cancer: moderate hypofractionated radiotherapy\u2014not yet a standard of care. Nat Rev Clin Oncol 13:655\u2013656","journal-title":"Nat Rev Clin Oncol"},{"key":"1175_CR7","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.ctrv.2013.01.008","volume":"39","author":"NG Zaorsky","year":"2013","unstructured":"Zaorsky NG, Ohri N, Showalter TN et al (2013) Systematic review of hypofractionated radiation therapy for prostate cancer. Cancer Treat Rev 39:728\u2013736","journal-title":"Cancer Treat Rev"},{"key":"1175_CR8","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","volume":"17","author":"D Dearnaley","year":"2016","unstructured":"Dearnaley D, Syndikus I, Mossop H, CHHiP Investigators et al (2016) Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol 17:1047\u20131060","journal-title":"Lancet Oncol"},{"key":"1175_CR9","doi-asserted-by":"crossref","unstructured":"Catton CN, Lukka H, Julian JA, et al (2016) A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. ASCO meeting abstracts 34:5003","DOI":"10.1200\/JCO.2016.34.15_suppl.5003"},{"key":"1175_CR10","first-page":"3","volume":"94","author":"WR Lee","year":"2016","unstructured":"Lee WR, Dignam JJ, Amin M et al (2016) NRG Oncology RTOG 0415: a randomized phase III non-inferiority study comparing two fractionation schedules in patients with low-risk prostate cancer. Int J Radiat Oncol Biol Phys 94:3\u20134","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1175_CR11","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S1470-2045(15)00567-7","volume":"17","author":"S Aluwini","year":"2016","unstructured":"Aluwini S, Pos F, Schimmel E et al (2016) Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomized, non-inferiority, phase 3 trial. Lancet Oncol 17:464\u2013474","journal-title":"Lancet Oncol"},{"key":"1175_CR12","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1016\/S1470-2045(15)00280-6","volume":"16","author":"A Wilkins","year":"2015","unstructured":"Wilkins A, Mossop H, Syndikus I et al (2015) Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol 16:1605\u20131616","journal-title":"Lancet Oncol"},{"key":"1175_CR13","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/nrclinonc.2015.29","volume":"6","author":"AA Secord","year":"2015","unstructured":"Secord AA, Coleman RL, Havrilesky LJ et al (2015) Patient-reported outcomes as end points and outcome indicators in solid tumours. Nat Rev Clin Oncol 6:358\u2013370","journal-title":"Nat Rev Clin Oncol"},{"key":"1175_CR14","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.critrevonc.2006.07.005","volume":"62","author":"BA Murphy","year":"2007","unstructured":"Murphy BA, Ridner S, Wells N et al (2007) Quality of life research in head and neck cancer: a review of the current state of the science. Crit Rev Oncol Hematol 62:251\u2013267","journal-title":"Crit Rev Oncol Hematol"},{"key":"1175_CR15","first-page":"243","volume-title":"TNM classification of malignant tumours","year":"2009","unstructured":"Sobin LH, Gospodarowicz MK, Wittekind C (eds) (2009) TNM classification of malignant tumours, 7th edn. Wiley-Blackwell, New York, pp 243\u2013248","edition":"7"},{"key":"1175_CR16","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/jama.280.11.969","volume":"280","author":"AV D\u2019Amico","year":"1998","unstructured":"D\u2019Amico AV, Whittington R, Malkowicz SB et al (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280:969\u2013974","journal-title":"JAMA"},{"key":"1175_CR17","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1080\/028418699431627","volume":"38","author":"B Lennern\u00e4s","year":"1999","unstructured":"Lennern\u00e4s B, Nilsson S (1999) Calculated effects of displacement errors in external beam radiotherapy of prostatic adenocarcinoma. Acta Oncol 38:203\u2013208","journal-title":"Acta Oncol"},{"key":"1175_CR18","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/0360-3016(95)00060-C","volume":"31","author":"JD Cox","year":"1995","unstructured":"Cox JD, Stetz J, Pajak TF (1995) Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31:1341\u20131346","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1175_CR19","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","volume":"65","author":"M Roach 3rd","year":"2006","unstructured":"Roach M 3rd, Hanks G, Thames H Jr et al (2006) Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65:965\u2013974","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1175_CR20","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1016\/j.juro.2007.01.066","volume":"177","author":"Y Kakehi","year":"2007","unstructured":"Kakehi Y, Takegami M, Suzukamo Y et al (2007) Health related quality of life in Japanese men with localized prostate cancer treated with current multiple modalities assessed by a newly developed Japanese version of the Expanded Prostate Cancer Index Composite. J Urol 177:1856\u20131861","journal-title":"J Urol"},{"issue":"2","key":"1175_CR21","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.ijrobp.2003.10.033","volume":"59","author":"T Akimoto","year":"2004","unstructured":"Akimoto T, Kitamoto Y, Saito J et al (2004) External beam radiotherapy for clinically node-negative, localized hormone-refractory prostate cancer: impact of pretreatment PSA value on radiotherapeutic outcomes. Int J Radiat Oncol Biol Phys 59(2):372\u2013379","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"1175_CR22","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.ijrobp.2004.07.695","volume":"60","author":"T Akimoto","year":"2004","unstructured":"Akimoto T, Muramatsu H, Takahashi M et al (2004) Rectal bleeding after hypofractionated radiotherapy for prostate cancer: correlation between clinical and dosimetric parameters and the incidence of grade 2 or worse rectal bleeding. Int J Radiat Oncol Biol Phys 60(4):1033\u20131039","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1175_CR23","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.ijrobp.2013.02.010","volume":"86","author":"N Patel","year":"2013","unstructured":"Patel N, Faria S, Cury F et al (2013) Hypofractionated radiation therapy (66\u00a0Gy in 22 fractions at 3\u00a0Gy per fraction) for favorable-risk prostate cancer: long-term outcomes. Int J Radiat Oncol Biol Phys 86:534\u2013539","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1175_CR24","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/j.ijrobp.2005.05.054","volume":"63","author":"PA Kupelian","year":"2005","unstructured":"Kupelian PA, Thakkar VV, Khuntia D et al (2005) Hypofractionated intensity-modulated radiotherapy (70\u00a0Gy at 2.5\u00a0Gy per fraction) for localized prostate cancer: long-term outcomes. Int J Radiat Oncol Biol Phys 63:1463\u20131468","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1175_CR25","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.semradonc.2007.09.006","volume":"18","author":"EF Miles","year":"2008","unstructured":"Miles EF, Lee WR (2008) Hypofractionation for prostate cancer: a critical review. Semin Radiat Oncol 18:41\u201347","journal-title":"Semin Radiat Oncol"},{"key":"1175_CR26","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.eururo.2014.08.009","volume":"68","author":"BF Koontz","year":"2015","unstructured":"Koontz BF, Bossi A, Cozzarini C et al (2015) A systematic review of hypofractionation for primary management of prostate cancer. Eur Urol 68:683\u2013691","journal-title":"Eur Urol"},{"key":"1175_CR27","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/S0360-3016(03)00752-1","volume":"57","author":"JE Livsey","year":"2003","unstructured":"Livsey JE, Cowan RA, Wylie JP et al (2003) Hypofractionated conformal radiotherapy in carcinoma of the prostate: five-year outcome analysis. Int J Radiat Oncol Biol Phys 57:1254\u20131259","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1175_CR28","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.ijrobp.2012.02.049","volume":"84","author":"S Arcangeli","year":"2012","unstructured":"Arcangeli S, Strigari L, Gomellini S et al (2012) Updated results and patterns of failure in a randomized hypofractionation trial for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 84:1172\u20131178","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1175_CR29","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1016\/S1470-2045(15)00280-6","volume":"16","author":"A Wilkins","year":"2015","unstructured":"Wilkins A, Mossop H, Syndikus I et al (2015) Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol 16:1605\u20131616","journal-title":"Lancet Oncol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10147-017-1175-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-017-1175-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-017-1175-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T16:30:50Z","timestamp":1569947450000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10147-017-1175-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,31]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["1175"],"URL":"https:\/\/doi.org\/10.1007\/s10147-017-1175-1","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,31]]}}}